Halozyme Therapeutics stock under bearish pressure with technicals pointing to likely short-term consolidation

Traders Union
All News
Companies
Halozyme Therapeutics down 2.07% today

Highlights

HALO closed at $67.15 after a 2.07% decline, trading below major moving averages and reinforcing short-term selling pressure.
Oscillators and intraday indicators signal oversold conditions, but mixed momentum suggests uncertain direction and low conviction among traders.
Price is likely to consolidate between $65.00 and $70.50 next week, with a bullish long-term trend despite near-term weakness.

Short-term selling pressure as price tests major support levels

HALO is trading at $67.15, just below the MA-50 ($67.79), MA-20 ($69.39), and MA-200 ($69.19), indicating short- and medium-term selling pressure but potential long-term support just under current levels. The Ichimoku Kijun sits at $69.75, serving as immediate resistance near-term. Near-term support is clustered around the MA-50 ($67.79), with key support at the EMA-200 ($66.84). Immediate resistance aligns with the Kijun ($69.75), while key resistance is set by the MA-20 and MA-200 ($69.39–$69.19).

Divergent momentum signals amid persistent downside and low conviction

Momentum on D1 is mixed, as MACD signals a strong buy while ADX remains weakly directional and neutral, reflecting low conviction. Oscillators such as RSI (48.5) and Stoch RSI (15.23) indicate a market close to oversold, reinforced by CCI’s neutral tone near the lower bound and pervasive oversold readings across intraday timeframes. BBP, however, points to overbought conditions, exposing a clear divergence among short-term indicators and suggesting unstable direction for both buyers and sellers. In today’s session, HALO has declined 2.07%, closing at the very bottom of the weekly range and amplifying the week’s bearish momentum. Over the past week, HALO has fallen $2.35 (3.43%) from a previous weekly close of $69.50, as weekly volatility stands at 6.34%. The persistent retreat from the week’s high spells steady downside pressure.

Bullish bias prevails as consolidation likely within support-resistance corridor

Looking ahead, the projected price corridor for the coming week stands at $65.00 to $70.50, keeping the range realistic relative to the current price and within the context of the 52-week span of $51.06 to $82.22. Based on the count of bullish W1 indicators (MA-50, MA-100, MA-200, and RSI all flashing "Buy"), the probability of price increases is very high (more than 80%). Probability of a decline is therefore very low. The baseline scenario sees HALO consolidating within the corridor, likely hovering between nearby support from MA-50 and resistance at the Kijun. A bullish break above $70.50 could trigger a test of $72, while a bearish breach below $65.00 may open the path toward the mid-$63s. The prevailing long-term trend remains bullish, but short-term pressure and this week’s technical weakness make a sideways move the most probable near term.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Halozyme Therapeutics was experiencing sustained weakness despite strong financial performance and strategic acquisitions. In light of recent developments, the prevailing scenario remains cautious, with traders advised to closely monitor shifts in momentum indicators for early signs of a potential reversal.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.